Dr. Carol Lim has received a HCI Cell Response and Regulation (CRR) grant for $30,000. ... Read More
The project uses animal seizure models and neuroscience techniques to help develop new antiepileptic agents. Some 800-1000 novel compounds per year are evaluated against conventional drugs for anticonvulsant efficacy and potency, neurotoxicity, effect on liver function, and mechanism of action. Promising compounds, which exhibit a high level and/or unusual spectrum of anticonvulsant activity with superior therapeutic potential, are selected for detailed toxicology studies and subsequent clinical trials in epileptic patients. The project has been continually funded since 1975 and every new anticonvulsant introduced to clinical use in the USA during the past 40 years has been evaluated in this research program.
The program is an integral part of the Department of Pharmacology and Toxicology and, as such, provides a site for research training of undergraduate students, departmental graduate students and postdoctoral fellows. Faculty aligned with the program also provide instruction to professional students in the College of Pharmacy and the School of Medicine.
ADD's College of Pharmacy’s Program Awarded $19.5M Contract Renewal To Identify Compounds for Treating Therapy-Resistant Epilepsy
Pharmaceutics Graduate Student Peng Zhao has been granted a 2017-2018 University of Utah Graduate Research Fellowship.... Read More
Jindrich Kopecek Received HCI Experimental Therapeutics Program Grant... Read More
Graduate student Sun Jin Kim receives department 2017 Jeffrey L. Fox Award. ... Read More
Dr. Carol Lim was awarded the 2017 College of Pharmacy Outstanding Teacher of the Year ... Read More
Dr. Margo Haygood, Medicinal Chemistry, joined by an international team of scientists, discover an elusive giant shipworm in the Philippines. ... Read More